In-hospital outcomes of lacosamide versus levetiracetam for early adjunctive treatment of status epilepticus: A Nationwide Japanese retrospective cohort study

Yumiko Nakamura; Shotaro Aso; Hideo Yasunaga; Hiroki Matsui; Yuichiro Shirota; Masashi Hamada; Kiyohide Fushimi; Tatsushi Toda; Satoshi Kodama

doi:10.1002/epi4.70182

Back

In-hospital outcomes of lacosamide versus levetiracetam for early adjunctive treatment of status epilepticus: A Nationwide Japanese retrospective cohort study

Journal article

Open access

Peer reviewed

In-hospital outcomes of lacosamide versus levetiracetam for early adjunctive treatment of status epilepticus: A Nationwide Japanese retrospective cohort study

Yumiko Nakamura, Shotaro Aso, Hideo Yasunaga, Hiroki Matsui, Yuichiro Shirota, Masashi Hamada, Kiyohide Fushimi, Tatsushi Toda and Satoshi Kodama

Epilepsia open, Vol.11(1), pp.162-169

02/2026

DOI: 10.1002/epi4.70182

PMID: 41222404

Files and links (1)

url

https://doi.org/10.1002/epi4.70182View

Published (Version of record) Open Access

Abstract

Status epilepticus (SE) is a neurological emergency requiring immediate treatment. Although intravenous lacosamide (LCM) is used for the management of epilepsy, its effectiveness in treating SE remains unclear. We aimed to compare the in-hospital outcomes between intravenous LCM and levetiracetam (LEV) as an early adjunctive therapy for SE using a nationwide inpatient Japanese database. We conducted an observational study using data extracted from the Japanese Diagnosis Procedure Combination database. Patients admitted for SE who received intravenous diazepam or lorazepam on the day of admission and were discharged between April 2019 and March 2023 were enrolled. Patients were categorized into those who received intravenous LCM or LEV on the day of admission. We compared the in-hospital outcomes (in-hospital mortality, length of hospital stay, total hospitalization costs, and proportion of patients with a Glasgow Coma Scale score [GCS] ≤9 at discharge) between the groups using propensity score overlap weighting. Among the 4605 eligible patients, 227 received LCM and 4378 received LEV. In the propensity score overlap-weighted cohort, in-hospital mortality (4.0% vs. 4.6%, adjusted risk difference [aRD], -0.28%; 95% confidence interval [CI], -3.3% to 2.7%), length of hospital stay (22.4 vs. 22.3 days; difference, 0.011; 95% CI, -3.9 to 3.9), and total hospitalization costs (1 167 798 JPY vs. 1 177 497 JPY; difference, 9699 JPY; 95% CI, -196 269 to 176 872 JPY) did not differ significantly between the LCM and LEV groups. The proportion of patients with GCS scores ≤9 at discharge was lower in the LCM group than in the LEV group (0.6% and 2.4%; aRD, -2.1%; 95% CI, -3.3% to -0.9%). LCM and LEV did not yield significantly different in-hospital mortality rates when used for early adjunctive treatment of SE. However, LCM may reduce poor neurological status at discharge. These results highlight the potential utility of LCM in the early management of SE. This study compared two intravenous antiseizure medications, levetiracetam (LEV) and lacosamide (LCM), as early add-on therapy for status epilepticus (SE), using data from a large Japanese inpatient database. The in-hospital mortality, length of hospital stay, or total medical costs did not differ significantly between the groups. However, patients treated with LCM had a lower chance of having a poor neurological status at discharge. While LEV is a well-established treatment for SE, this study suggests that LCM may be similarly effective and could offer an advantage, although more research is needed.

Adult

Aged

Aged, 80 and over

Anticonvulsants - administration & dosage

Anticonvulsants - therapeutic use

Cohort Studies

East Asian People

Female

Hospital Mortality

Humans

Japan - epidemiology

Lacosamide - administration & dosage

Lacosamide - therapeutic use

Length of Stay - statistics & numerical data

Levetiracetam - therapeutic use

Male

Middle Aged

Retrospective Studies

Status Epilepticus - drug therapy

Status Epilepticus - mortality

Treatment Outcome

Details

Title: Subtitle: In-hospital outcomes of lacosamide versus levetiracetam for early adjunctive treatment of status epilepticus: A Nationwide Japanese retrospective cohort study
Creators: Yumiko Nakamura - The University of Tokyo
Shotaro Aso - The University of Tokyo
Hideo Yasunaga - University of Tokyo Health Sciences
Hiroki Matsui - University of Tokyo Health Sciences
Yuichiro Shirota - The University of Tokyo
Masashi Hamada - The University of Tokyo
Kiyohide Fushimi - Institute for Health Economics and Policy
Tatsushi Toda - The University of Tokyo
Satoshi Kodama - University of Iowa Hospitals and Clinics
Resource Type: Journal article
Publication Details: Epilepsia open, Vol.11(1), pp.162-169
DOI: 10.1002/epi4.70182
PMID: 41222404
NLM abbreviation: Epilepsia Open
ISSN: 2470-9239
eISSN: 2470-9239
Language: English
Date published: 02/2026
Academic Unit: Neurology
Record Identifier: 9985177941302771

Metrics

1 Record Views

1 Times Cited - Web of Science